(Q38613615)

4 September 2017

title

Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer (English)

1 reference

4 September 2017

0 references

Amanda Rounds

1

1 reference

4 September 2017

Jill Kolesar

series ordinal

2

1 reference

4 September 2017

publication date

1 November 2015

1 reference

American Journal of Health-System Pharmacy

4 September 2017

published in

1 reference

4 September 2017

volume

72

1 reference

4 September 2017

issue

21

1 reference

4 September 2017

page(s)

1851-1855

1 reference

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150235

31 March 2020

Identifiers

DOI

10.2146/AJHP150235

1 reference

4 September 2017

1 reference